The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
May. 31, 2016

Filed:

Nov. 24, 2010
Applicants:

Zeljko M. Prijovic, Taipei, TW;

Yu-lin Leu, Tainan, TW;

Steve R. Roffler, Taipei, TW;

Inventors:

Zeljko M. Prijovic, Taipei, TW;

Yu-Lin Leu, Tainan, TW;

Steve R. Roffler, Taipei, TW;

Assignee:

Academia Sinica, Taipei, TW;

Attorney:
Primary Examiner:
Assistant Examiner:
Int. Cl.
CPC ...
A61K 31/706 (2006.01); C07H 15/26 (2006.01); A61P 35/00 (2006.01); C07H 15/203 (2006.01);
U.S. Cl.
CPC ...
C07H 15/203 (2013.01);
Abstract

The invention relates to the synthesis of a second-generation camptothecin glucuronide prodrug (BQC-G) of a potent anticancer camptothecin derivative 5,6-dihydro-4H-benzo[de]quinoline-camptothecin (BQC). BQC-G was over 4000 times more water soluble than BQC, displayed good stability in human plasma and was an excellent substrate for enzymatic hydrolysis by bacterial and human β-glucuronidases. BQC-G was about 30 times less toxic than BQC, but was as toxic as BQC after hydrolysis of the glucuronide moiety by β-glucuronidase. In the presence of human serum albumin, BQC-G displayed lower cytotoxicity (IC=1080 nM) but could be activated by β-glucuronidase to display potent activity (IC=13.3 nM).


Find Patent Forward Citations

Loading…